WellSpan Health, a Pennsylvania-based health system, announced on July 30, 2026 that it is expanding its multi-year partnership with Hippocratic AI to deploy its conversational voice agent, known as Ana, platform-wide across inpatient and ambulatory care. Ana already handles more than 160,000 patient calls and 7,000 conversational hours each month, making it one of the largest deployments of an autonomous healthcare voice agent in the country.
What Ana Actually Does
Ana is a generative AI voice assistant that speaks with patients over the phone in natural, personalized conversation rather than routing them through a rigid phone tree. The system calls patients to encourage participation in at-home colorectal cancer screenings, notifies patients of negative mammogram results while reinforcing the importance of annual screening, answers primary-care lines on the first ring, and switches fluidly between languages mid-conversation to match a patient’s preference. WellSpan first launched an early version of the tool in 2024, positioning itself as one of the first major health systems in the world to deploy Hippocratic AI’s generative healthcare agent.
Why Health Systems Are Turning to Voice AI
The expansion reflects a stubborn structural problem in American healthcare: understaffed call centers and administrative teams that cannot keep pace with patient outreach needs, especially for preventive screenings that save lives but are notoriously hard to get patients to schedule. Healthcare IT surveys cited by industry publications have found that a meaningful share of patients have put off canceling an appointment simply because doing so required a phone call, underscoring how much friction exists in basic phone-based interactions. Voice AI agents promise to remove that friction by being available around the clock without adding headcount.
The Skeptics’ Case
Not every observer is enthusiastic. Patient advocates and some clinicians worry that outsourcing sensitive interactions, like communicating mammogram results, to an AI voice risks depersonalizing moments that matter enormously to patients, even when the news is reassuring. There are also open questions about how these systems handle edge cases, such as a patient who reveals a health crisis mid-call about screening logistics, and whether human escalation protocols are robust enough to catch those moments reliably. Regulatory clarity is still catching up; several states are separately weighing restrictions on AI in more clinically sensitive roles, such as therapy, reflecting broader public unease about where the line should be drawn between administrative automation and clinical judgment.
WellSpan’s Counter-Argument
WellSpan executives describe Ana as freeing human staff to focus on more complex patient needs rather than repetitive scheduling and reminder calls. The health system plans to extend Ana’s role into proactive outbound outreach for missed imaging appointments, post-discharge follow-ups and chronic disease monitoring, arguing that more, not less, human contact will be possible once routine calls are automated. WellSpan has framed the partnership as improving both operational efficiency and the patient experience simultaneously, rather than a cost-cutting measure alone.
Part of a Broader Industry Shift
WellSpan is not alone. Becker’s Hospital Review has tracked at least a dozen health systems expanding their use of agentic AI for tasks ranging from scheduling to chronic care check-ins, and Hippocratic AI has become one of the most closely watched vendors in this space precisely because of the scale WellSpan has demonstrated. The company’s approach, layering AI on top of existing phone infrastructure rather than requiring patients to adopt new apps or portals, has proven easier to roll out quickly compared with other digital health tools that depend on patient engagement.
What’s Next
As WellSpan scales Ana across its full network, the health system says it will track patient satisfaction and screening completion rates to justify further expansion. Analysts expect other systems to follow suit through the rest of 2026, particularly for chronic disease monitoring, where proactive outreach has the clearest potential to reduce costly emergency visits and hospital readmissions.
Measuring Success Beyond Call Volume
WellSpan executives say they are tracking more than raw call volume as they scale Ana, including patient satisfaction scores, screening completion rates and how often calls require escalation to a human staff member. Healthcare consultants who study patient engagement technology note that voice AI adoption tends to succeed or fail based on how gracefully it handles edge cases outside its training, meaning WellSpan’s ongoing investment in refining escalation protocols will likely determine whether Ana’s expansion continues to be viewed as a patient experience improvement rather than a source of frustration. Other health systems watching WellSpan’s rollout say they are waiting for more published outcome data, beyond call volume figures, before committing to similarly large-scale voice AI deployments of their own.
